Trusted Resources: Education
Scientific literature and patient education texts
Amyloidosis Information: A General Overview for Patients
source: Amyloidosis Foundation
year: 2020
summary/abstract:The amyloidoses (the plural word for amyloidosis) are rare diseases first described over 150 years ago. There are different types of amyloidosis that are all unified by a common pathological process. Amyloid diseases all cause deposits of amyloid proteins in the body’s organs and tissue, and the amyloidoses are classified by the protein that deposits as amyloid. This accumulation may happen systemically (throughout the body) or locally (in one tissue or organ).
Each year approximately 3000-5000 new cases of light chain (AL) amyloidosis are diagnosed in the United States, with many more cases of age-related and inherited transthyretin amyloidosis (ATTR) also diagnosed. Amyloidosis is generally a disease of middle-aged people and older, although the disease has been seen in individuals in their thirties.
Other diseases can increase the risk of amyloidosis, and family history of the disease may indicate a hereditary version. 10 to 15% of people with multiple myeloma develop amyloidosis. Long-term kidney dialysis may increase the risk of dialysis-associated amyloidosis.
read moreRelated Content
-
Methodist Blood and Marrow Transplant CenterThe Methodist Blood and Marrow Transplan...
-
Amyloidosis Diagnosis, Treatment Concepts, and Future – Dr. Mark Pepyshttps://www.youtube.com/watch?v=31xThMYI...
-
Inotersen: An Exciting Prospect for hATTR Amyloidosis TreatmentA new hereditary ATTR (hATTR) amyloidosi...
-
Managing Physical Side EffectsCancer and cancer treatment often cause ...
-
Safety and Efficacy of Long-Term Diflunisal Administration in Hereditary Transthyretin (ATTR) AmyloidosisBackground: A recent 2-year randomized ...
-
Macroglossia in Light-Chain AmyloidosisA 78-year-old man presented to the emerg...
-
FDA Approves Subcutaneous Daratumumab Plus VCd for Newly Diagnosed Light-Chain AmyloidosisThe FDA has approved daratumumab and h...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.